Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Short term Debt (2020 - 2025)

Historic Short term Debt for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to $13.5 million.

  • Rani Therapeutics Holdings' Short term Debt fell 833.56% to $13.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.5 million, marking a year-over-year decrease of 833.56%. This contributed to the annual value of $15.0 million for FY2024, which is 20631.0% up from last year.
  • As of Q3 2025, Rani Therapeutics Holdings' Short term Debt stood at $13.5 million, which was down 833.56% from $15.0 million recorded in Q2 2025.
  • Over the past 5 years, Rani Therapeutics Holdings' Short term Debt peaked at $15.0 million during Q4 2024, and registered a low of $30000.0 during Q2 2022.
  • For the 5-year period, Rani Therapeutics Holdings' Short term Debt averaged around $7.0 million, with its median value being $4.9 million (2023).
  • Its Short term Debt has fluctuated over the past 5 years, first crashed by 9922.76% in 2022, then soared by 212181.82% in 2023.
  • Rani Therapeutics Holdings' Short term Debt (Quarter) stood at $126000.0 in 2021, then plummeted by 56.35% to $55000.0 in 2022, then skyrocketed by 8803.64% to $4.9 million in 2023, then soared by 206.31% to $15.0 million in 2024, then dropped by 9.75% to $13.5 million in 2025.
  • Its Short term Debt was $13.5 million in Q3 2025, compared to $15.0 million in Q2 2025 and $15.0 million in Q1 2025.